The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
 
Ronan Joseph Kelly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Clovis Oncology; EMD Serono; Gritstone Bio; Lilly; Novartis; OncoMed
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Jeeyun Lee
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - BeiGene; Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Khaldoun Almhanna
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Merck
Speakers' Bureau - Genentech/Roche
 
Mariela A. Blum Murphy
Honoraria - EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Genmab; Gritstone Bio; Guardant Health; Lilly; Merck; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Guardant Health
Research Funding - Genentech; OncoPlex Diagnostics
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Michael Gibson
Honoraria - Amgen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - NCCN
 
Keun Wook Lee
Research Funding - Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst)
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Crystal S. Denlinger
Consulting or Advisory Role - Carevive Systems; EMD Serono; Lilly; Merck; Merrimack
Research Funding - Advaxis (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst)
 
Philip Z. Brohawn
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Peng He
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jennifer McDevitt
Employment - MedImmune; Tempest Therapeutics
 
Judson Englert
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - Johns Hopkins University
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme
Research Funding - Aduro Biotech (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme